Gsk (GSK) Receivables (2009 - 2026)

Gsk (GSK) has 18 years of Receivables data on file, last reported at $10.3 billion in Q2 2026.

• For the quarter ending Q2 2026, Receivables rose 5.86% year-over-year to $10.3 billion; the trailing twelve-month figure through Jun 2026 stood at $10.3 billion (up 5.86% YoY), and the FY2025 full-year result was $11.5 billion, up 16.57% from the prior year.
• Receivables was $10.3 billion for Q2 2026 at Gsk, down from $10.5 billion in the prior quarter.
• In the past five years, Receivables ranged from a high of $18.4 billion in Q1 2022 to a low of $8.1 billion in Q2 2022.
• A 5-year average of $10.1 billion and a median of $9.7 billion in 2025 frame the typical range for Receivables.
• Across the five-year window, Receivables soared 106.03% in 2022 and tumbled 54.97% in 2023, its largest moves.
• Gsk's Receivables stood at $9.7 billion in 2022, then advanced by 7.75% to $10.5 billion in 2023, then retreated by 5.63% to $9.9 billion in 2024, then grew by 16.1% to $11.5 billion in 2025, then decreased by 9.81% to $10.3 billion in 2026.
• Per Business Quant data, the three most recent Receivables figures were $10.3 billion in Q2 2026, $10.5 billion in Q1 2026, and $11.5 billion in Q4 2025.